A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Libtayo may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

According to the September announcement, a median overall survival of 26 months was seen in the Libtayo treatment group, compared to 13 months in the chemotherapy cohort, and median progression-free ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed ...

LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed significant ...